TABLE 2.
Fold changes of antibiotic (CTX, AMP, or CIP)-induced increased conjugation transfer frequency using ESBL E. coli as donors and J53-2 as recipient.
| Donor | Conjugation time (min) | Conjugation transfer frequencya (Control) | Conjugation transfer frequencya (CTX) | Fold changeb | Conjugation transfer frequencya (AMP) | Fold changeb | Conjugation transfer frequencya (CIP) | Fold changeb |
| MG1655/pTF2 (IncI1/CTX-M-1) | 30 | 4.63 × 10–3 ± 1.25 × 10–3 | 2.93 × 10–2 ± 0.23 × 10–2 | 6.3∗∗ | 1.30 × 10–2 ± 0.11 × 10–3 | 2.8∗ | 5.73 × 10–3 ± 0.80 × 10–3 | 1.2 |
| 60 | 1.11 × 10–2 ± 0.24 × 10–2 | 4.09 × 10–2 ± 0.24 × 10–2 | 3.7∗∗ | 6.11 × 10–2 ± 0.51 × 10–2 | 5.5∗ | 6.97 × 10–2 ± 1.04 × 10–2 | 6.3∗ | |
| ESBL 4 (IncI1/CTX-M-1) | 30 | 4.11 × 10–4 ± 0.73 × 10–4 | 1.04 × 10–3 ± 0.39 × 10–3 | 2.5 | 3.63 × 10–3 ± 1.13 × 10–3 | 8.8 | 1.39 × 10–3 ± 0.33 × 10–3 | 4.7 |
| 60 | 5.71 × 10–4 ± 0.74 × 10–4 | 1.9 × 10–3 ± 0.38 × 10–3 | 3.3∗ | 6.53 × 10–3 ± 0.67 × 10–3 | 11.3∗ | 4.67 × 10–3 ± 0.70 × 10–3 | 8.1∗ | |
| ESBL 10 (IncI1/CTX-M-1) | 30 | 1.04 × 10–2 ± 0.12 × 10–2 | 3.62 × 10–2 ± 1.22 × 10–2 | 3.5 | 2.93 × 10–2 ± 0.28 × 10–2 | 2.8∗ | 2.44 × 10–2 ± 0.58 × 10–2 | 2.3 |
| 60 | 1.17 × 10–2 ± 0.11 × 10–2 | 1.02 × 10–1 ± 0.11 × 10–1 | 8.7∗ | 2.97 × 10–2 ± 0.31 × 10–2 | 2.5∗ | 5.26 × 10–2 ± 1.21 × 10–2 | 4.5 | |
| ESBL 12 (IncI1/CTX-M-1) | 30 | 8.46 × 10–5 ± 1.69 × 10–5 | 2.44 × 10–4 ± 0.16 × 10–4 | 2.9∗ | 2.85 × 10–4 ± 0.55 × 10–4 | 3.3 | 1.47 × 10–4 ± 0.19 × 10–4 | 1.7 |
| 60 | 1.47 × 10–4 ± 0.09 × 10–4 | 1.77 × 10–3 ± 0.38 × 10–3 | 12.0∗ | 6.63 × 10–4 ± 1.24 × 10–4 | 4.5∗ | 5.61 × 10–4 ± 1.42 × 10–4 | 3.8 | |
| ESBL 17 (IncI1/CTX-M-1) | 30 | 2.63 × 10–5 ± 0.33 × 10–5 | 5.61 × 10–5 ± 0.72 × 10–5 | 2.1∗ | 3.35 × 10–5 ± 1.41 × 10–5 | 1.2 | 3.20 × 10–5 ± 1.41 × 10–5 | 1.2 |
| 60 | 4.15 × 10–5 ± 1.07 × 10–5 | 1.09 × 10–4 ± 0.20 × 10–4 | 2.6∗ | 4.20 × 10–5 ± 1.54 × 10–5 | 1.0 | 3.29 × 10–5 ± 0.95 × 10–5 | 0.8 | |
| ESBL 21 (IncI1/CTX-M-55) | 30 | 2.73 × 10–3 ± 0.40 × 10–3 | 8.96 × 10–3 ± 1.99 × 10–3 | 3.3 | 8.63 × 10–3 ± 2.03 × 10–3 | 3.2 | 9.34 × 10–3 ± 0.66 × 10–3 | 3.4 |
| 60 | 5.41 × 10–3 ± 0.18 × 10–2 | 1.62 × 10–2 ± 0.27 × 10–2 | 3.3∗ | 1.45 × 10–2 ± 0.11 × 10–3 | 2.7∗ | 1.30 × 10–2 ± 0.15 × 10–2 | 2.4 | |
| ESBL 22 (IncF/CTX-M-14) | 30 | 1.61 × 10–4 ± 0.36 × 10–4 | 5.91 × 10–4 ± 1.18 × 10–4 | 3.7∗ | 9.3 × 10–4 ± 0.95 × 10–4 | 5.8∗ | 9.67 × 10–4 ± 0.94 × 10–4 | 6.0∗ |
| 60 | 2.72 × 10–4 ± 0.94 × 10–4 | 8.69 × 10–4 ± 2.26 × 10–4 | 3.2 | 1.37 × 10–3 ± 0.14 × 10–3 | 5.0∗ | 1.22 × 10–3 ± 0.19 × 10–3 | 4.5∗ | |
| ESBL 23 (IncF/CTX-M-14) | 30 | 2.70 × 10–4 ± 0.17 × 10–4 | 7.35 × 10–4 ± 0.55 × 10–4 | 2.7∗ | 3.11 × 10–4 ± 0.28 × 10–4 | 0.9 | 2.87 × 10–4 ± 0.22 × 10–4 | 1.1 |
| 60 | 3.98 × 10–4 ± 0.70 × 10–4 | 1.07 × 10–3 ± 0.18 × 10–3 | 2.7∗ | 3.79 × 10–4 ± 0.55 × 10–4 | 1.0 | 4.28 × 10–4 ± 0.35 × 10–4 | 1.1 |
aThe results shown are from two biological replicates with three technical replicates each, the data shown represent the mean ± standard deviation. bThe asterisks indicate statistical significance between antibiotic treated and control at level: ∗P ≤ 0.05, ∗∗P ≤ 0.01.